VEA
MBX

Virtus ETF Advisers’s MBX Biosciences MBX Stock Holding History

Virtus ETF Advisers’s Portfolio MBX Stock Details MBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,468
Closed -$63.9K – 821
2024
Q4 		$63.9K Buy
+3,468
New +$73.9K 0.03% 427

Other funds holding MBX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Virtus ETF Advisers's MBX Position: Q1 2025 in Review

Virtus ETF Advisers sold out of MBX Biosciences (MBX) in Q1 2025, closing a stake of 3,468 shares — an estimated $63.9K sold.

Virtus ETF Advisers first reported a position in MBX in Q4 2024 and held it in 1 quarter. The position peaked at $63.9K in Q4 2024. 79 funds tracked by Wall St. Rank hold MBX as of Q1 2025.

  • Virtus ETF Advisers reported no remaining MBX Biosciences position as of Q1 2025 after selling out during the quarter.
  • Virtus ETF Advisers sold 3,468 MBX Biosciences shares in Q1 2025, an estimated $63.9K.
  • Virtus ETF Advisers first reported a position in MBX Biosciences in Q4 2024 and held it in 1 quarter.
  • Virtus ETF Advisers's MBX Biosciences position peaked at $63.9K in Q4 2024.
  • 79 funds tracked by Wall St. Rank held MBX Biosciences as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.